Fortacin

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
22-09-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
22-09-2023

Viambatanisho vya kazi:

lidocaine, prilocaine

Inapatikana kutoka:

Recordati Ireland Ltd.

ATC kanuni:

N01BB20

INN (Jina la Kimataifa):

lidocaine, prilocaine

Kundi la matibabu:

Anesthetics

Eneo la matibabu:

Sexual Dysfunction, Physiological

Matibabu dalili:

Treatment of primary premature ejaculation in adult men.

Bidhaa muhtasari:

Revision: 12

Idhini hali ya:

Authorised

Idhini ya tarehe:

2013-11-15

Taarifa za kipeperushi

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE USER
FORTACIN 150 MG/ML + 50 MG/ML
CUTANEOUS SPRAY, SOLUTION
lidocaine/prilocaine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always use this medicine exactly as described in this leaflet or as
your doctor or pharmacist have told
you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse.
WHAT IS IN THIS LEAFLET
1.
What Fortacin is and what it is used for
2.
What you need to know before you use Fortacin
3.
How to use Fortacin
4.
Possible side effects
5.
How to store Fortacin
6.
Contents of the pack and other information
1.
WHAT FORTACIN IS AND WHAT IT IS USED FOR
Fortacin is a combination of two medicines: lidocaine and prilocaine.
These belong to a group of
medicines called local anaesthetics.
Fortacin is indicated for the treatment of premature ejaculation
occurring in adult men (aged 18 years
and over) from first sexual intercourse. This is when you always, or
nearly always, have ejaculated
within one minute of sexual intercourse and this causes you negative
emotional effects. Fortacin works
by decreasing the sensitivity of the head of the penis to increase
time before ejaculation.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE FORTACIN
DO NOT USE FORTACIN
•
if you or your partner are allergic to lidocaine or prilocaine or any
of the other ingredients of
this medicine (listed in section 6);
•
if you or your partner have a history of allergy or sensitivity to
other local anaesthetics with a
similar structure (known as amide-type local anaesthetics).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before using Fortacin
•
if you, or your partner, have been diagnosed with a genetic disea
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Fortacin 150 mg/ml + 50 mg/ml cutaneous spray, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of solution contains 150 mg lidocaine and 50 mg prilocaine.
Each actuation delivers 50 microlitres which contains 7.5 mg lidocaine
and 2.5 mg prilocaine.
1 dose is equal to 3 actuations.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Cutaneous spray, solution
Colourless to light yellow solution
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Fortacin is indicated for the treatment of primary premature
ejaculation in adult men.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 3 actuations applied to cover the glans penis.
Each dose consists of a total
of 22.5 mg lidocaine and 7.5 mg prilocaine per application (1 dose is
equal to 3 actuations).
A maximum of 3 doses can be used within 24 hours with at least 4 hours
between doses.
Special populations
_Elderly _
Dose adjustments are not required in the elderly (see section 5.1).
_Renal impairment _
Clinical studies have not been performed in patients with impaired
renal function, however due to its
method of administration and very low systemic absorption, no dosage
adjustment is required.
_Hepatic impairment _
Clinical studies have not been performed in patients with impaired
hepatic function, however due to its
method of administration and very low systemic absorption, no dosage
adjustment is required. Caution
is advised in case of severe hepatic impairment (see section 4.4).
_Paediatric population _
There is no relevant use of Fortacin in the paediatric population for
the indication of treatment of
primary premature ejaculation.
Method of administration
Cutaneous use.
3
Fortacin is only indicated for application to the glans penis.
Before initial use, the spray container should be briefly shaken and
then primed by spraying it into the
air three times.
Before each subsequent use, it should be briefly shaken and then the
spray 
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kireno 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 08-12-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 22-09-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 22-09-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 22-09-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 22-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 08-12-2014

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati